Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Colonic Angioectasia in an Adolescent Boy with Hoyeraal-Hreidarsson on Long-Term Anabolic Steroid Therapy

  • Khalaf, Racha (Department of Pediatrics, Johns Hopkins All Children's Hospital, The Johns Hopkins University School of Medicine) ;
  • Cuffari, Carmen (Division of Pediatric Gastroenterology, The Johns Hopkins Hospital)
  • Received : 2017.06.16
  • Accepted : 2017.07.15
  • Published : 2018.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Androgen therapy has proven efficacy in treating patients with bone marrow failure who are not candidates for bone marrow transplantation. Herein, we report on a case of colonic angioectasia secondary to oxymetholone use in an adolescent patient with Hoyeraal-Hreidarsson syndrome (HHS). A 13-year-old Caucasian male with HHS characterized by cerebellar hypoplasia, developmental delay, microcephaly, esophageal strictures and myelodysplasia presented with severe hematochezia from colonic angioectasia secondary to long-term oxymetholone therapy. These vascular lesions resolved spontaneously once this anabolic steroid was discontinued. While androgen therapy is often recommended for certain anemias and myelodysplastic syndromes, clinicians should be aware of the potential complication in developing these perceived uncommon colonic angioectasias. Moreover, pediatric gastroenterologists should familiarize themselves in identifying these vascular lesions by colonoscopy, especially among the high risk groups on long-term anabolic steroid therapy.

Keywords

References

  1. Glousker G, Touzot F, Revy P, Tzfati Y, Savage SA. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol 2015;170:457-71. https://doi.org/10.1111/bjh.13442
  2. Ohga S, Kai T, Honda K, Nakayama H, Inamitsu T, Ueda K. What are the essential symptoms in the Hoyeraal-Hreidarsson syndrome? Eur J Pediatr 1997; 156:80-1.
  3. Islam A, Rafiq S, Kirwan M, Walne A, Cavenagh J, Vulliamy T, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol 2013;162:854-6. https://doi.org/10.1111/bjh.12432
  4. Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. Br J Haematol 2014;165:349-57. https://doi.org/10.1111/bjh.12748
  5. Shimamura A, Alter BP. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev 2010;24:101-22. https://doi.org/10.1016/j.blre.2010.03.002
  6. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd. Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001;23:789-801; discussion 771. https://doi.org/10.1016/S0149-2918(01)80070-9
  7. Brown KE, Kelly TE, Myers BM. Gastrointestinal involvement in a woman with dyskeratosis congenita. Dig Dis Sci 1993;38:181-4. https://doi.org/10.1007/BF01296794
  8. Andriole GL, Brickman C, Lack EE, Sesterhenn IA, Javadpour N, Linehan WM, et al. Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. J Urol 1986; 135:44-6. https://doi.org/10.1016/S0022-5347(17)45509-1